½ÃÀ庸°í¼­
»óǰÄÚµå
1586206

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå : Á¦Ç° À¯Çü, µðÀÚÀÎ, ¼ÒÀç, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Central Venous Catheters Market by Product Type, Design, Material, Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 197 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀåÀº 2023³â¿¡ 23¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 25¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 9.65%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 44¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC)´Â Áß½ÉÁ¤¸Æ¼øÈ¯¿¡ Á¢±ÙÇÏ¿© Àå½Ã°£ Á¤¸Æ ³» Ä¡·á, ¾à¹° Åõ¿© ¹× Ç÷¿ªÇÐ ¸ð´ÏÅ͸µÀ» À§ÇØ »ç¿ëµÇ´Â Ư¼ö ÀÇ·á±â±â·Î, CVCÀÇ Çʿ伺Àº È­Çпä¹ý, Åõ¼®, Àå±â Åõ¾à µî ½ÇÁúÀûÀÎ Á¤¸Æ Á¢±ÙÀÌ ÇʼöÀûÀÎ ÁßȯÀÚ Ä¡·á »óȲ¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. CVCÀÇ Àû¿ë ¹üÀ§´Â º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÀçÅÃÄ¡·á¿¡ À̸£±â±îÁö ºñ°æ±¸ ¿µ¾ç ¹× ¾à¹° Àü´Þ µî ´Ù¾çÇÑ ½Ã¼ú¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. CVC ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ¾Ï, ½ÅºÎÀü µî ¸¸¼º Áúȯ Áõ°¡, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Ä«Å×ÅÍÀÇ ¾ÈÀü¼º°ú ±â´É¼ºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå °³Ã´ÀÇ °úÁ¦´Â °¨¿° À§ÇèÀ» ÁÙÀ̱â À§ÇÑ Ç×±Õ ÄÚÆÃ Ä«Å×ÅÍ ¹× »ýüÀûÇÕ¼º Àç·áÀÇ °³¹ß¿¡ ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ëÀÀ, ³ôÀº ½Ã¼ú ºñ¿ë, Ä«Å×ÅÍ °ü·Ã ÇÕº´Áõ ´ëó µîÀÌ ¼ºÀåÀÇ Á¦¾à¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ È®´ëµÇ°í ÀÖ¾î ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àü·«Àû ÁýÁßÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ Ä«Å×ÅÍ µðÀÚÀÎ °³¼±, ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» À§ÇÑ ½º¸¶Æ® ±â¼ú ÅëÇÕ, ģȯ°æ ¼ÒÀç °³¹ß µîÀ» ¿¬±¸ °³¹ßÀÇ ¸ñÇ¥·Î »ï´Â °ÍÀÌ Áö¼Ó °¡´ÉÇÑ »ç¾÷ ¼ºÀåÀ» À§ÇÑ ÇÙ½É Àü·«ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ´Â Çù·ÂÀû ¼º°ÝÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ±â¾÷Àº R&D ÅõÀÚ¸¦ ¿ì¼±½ÃÇϰí, ÀÎÇÁ¶ó ¹®Á¦¸¦ ÇØ°áÇϰí, µðÁöÅÐ °Ç°­ÀÇ Áøº¸¸¦ Ȱ¿ëÇϱâ À§ÇØ Çù·ÂÀû Á¢±Ù ¹æ½ÄÀ» äÅÃÇØ¾ß ÇÕ´Ï´Ù. °æÀï ¾Ð·Â°ú ¾ö°ÝÇÑ ±ÔÁ¦°¡ °É¸²µ¹ÀÌ µÇÁö¸¸, ȯÀÚ Áß½ÉÀÇ Á¦Ç° °³¹ßÀ» ¼ö¿ëÇϰí ÃæÁ·µÇÁö ¾ÊÀº ½ÃÀå ¿ä±¸¸¦ ¼ö¿ëÇÔÀ¸·Î½á CVC ºÎ¹®ÀÇ ¼ºÀå ±Ëµµ¸¦ ÀçÁ¤ÀÇÇϰí ÁøÈ­ÇÏ´Â ÀÇ·á ¼ö¿ä¿¡ ÀûÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 23¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 25¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 44¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 9.65%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³ëÀÎ Àα¸ Áõ°¡¿Í ÀÇ·á ¹× º¹Áö ÁöÃâ Áõ°¡
    • ȯÀڵ鿡°Ô ¾Ï Ä¡·á¸¦ Á¦°øÇϱâ À§ÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡
    • Ç×±Õ Ä«Å×ÅÍÀÇ Àα⠻ó½Â
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Áß½ÉÁ¤¸Æ Ä«Å×ÅÍÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • »õ·Î¿î Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ °³¹ß
    • ¾Ï Ä¡·á Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå °úÁ¦
    • Áß½ÉÁ¤¸Æ Á¢±Ù¹ýÀÇ Àå±â »ç¿ë¿¡ µû¸¥ ÇÕº´Áõ

Portre's Five Forces: Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

½ÉÀå Á¤¸Æ Ä«Å×ÅÍ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå : Á¦Ç° À¯Çüº°

  • Implanted Ports
  • Non-Tunneled Central Venous Catheters
  • Peripherally Inserted CVCs
  • Tunneled Central Venous Catheters

Á¦7Àå Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå : µðÀÚÀκ°

  • ´õºí ·ç¸à Á᫐ Á¤¸Æ Ä«Å×ÅÍ
  • ¸ÖƼ ·ç¸à Á᫐ Á¤¸Æ Ä«Å×ÅÍ
  • ½Ì±Û ·ç¸à Á᫐ Á¤¸Æ Ä«Å×ÅÍ

Á¦8Àå Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå : ¼ÒÀ纰

  • Æú¸®¿ì·¹Åº
  • °í¹«
  • ½Ç¸®ÄÜ

Á¦9Àå Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå : ¿ëµµº°

  • ¼öÇ÷
  • Áø´Ü ¹× Å×½ºÆ®
  • ÀǾàǰ °ü¸®
  • ¼öºÐ ¹× ¿µ¾ç Åõ¿©

Á¦10Àå Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á᫐ Á¤¸Æ Ä«Å×ÅÍ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Amecath Medical Technologies
  • Angio Dynamics
  • B. Braun Melsungen AG
  • Bactiguard AB
  • Becton, Dickinson and Company
  • Biosensors International Group, Ltd.
  • BL Lifesciences Pvt. Ltd.
  • C.R. Bard
  • Fresenius Kabi AG
  • Henan Tuoren Medical Device Co., Ltd.
  • ICU Medical, Inc.
  • Insung Medical
  • Kimal Healthcare
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • Medical Components, Inc.
  • Medtronic PLC
  • Polymedicure
  • QMD by Cirtec Medical
  • Vogt Medical Vertrieb GmbH
  • Vygon SAS
LSH

The Central Venous Catheters Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.56 billion in 2024, and is projected to grow at a CAGR of 9.65%, to USD 4.47 billion by 2030.

Central Venous Catheters (CVCs) are specialized medical devices used to access the central venous circulation, providing prolonged intravenous therapy, medication administration, or hemodynamic monitoring. The necessity for CVCs arises in critical care scenarios where substantial intravenous access is essential, including chemotherapy, dialysis, and long-term medication delivery. The application scope of CVCs spans hospitals, ambulatory surgical centers, and home healthcare settings, catering to diverse procedures like parenteral nutrition or drug delivery. The end-use scope encompasses healthcare providers focused on improving patient outcomes through advanced medical interventions. Key growth drivers in the CVC market include increasing incidences of chronic diseases like cancer and kidney failure, rising demand for minimally invasive procedures, and technological advancements enhancing catheter safety and functionality. Emerging opportunities lie in developing antimicrobial-coated catheters and biocompatible materials to reduce infection risks, a significant challenge in this market. Navigating regulatory compliance, tackling high procedural costs, and addressing catheter-related complications pose limitations to growth. Despite these hurdles, expanding healthcare infrastructure in emerging economies offers lucrative prospects for market expansion, demanding a strategic focus on cost-effective solutions. Research and innovation should target enhancing catheter design to minimize complications, integrating smart technologies for real-time monitoring, and developing eco-friendly materials, which could foster sustainable business growth. The CVC market is competitive yet characterized by a collaborative nature fostering technological innovation through partnerships and acquisitions. Companies must prioritize R&D investments and adopt collaborative approaches to address infrastructural challenges and harness digital health advances. While competitive pressures and stringent regulations remain obstacles, embracing patient-centric product development and capturing unmet market needs can redefine growth trajectories in the CVC sector, ensuring it adapts to evolving healthcare demands.

KEY MARKET STATISTICS
Base Year [2023] USD 2.34 billion
Estimated Year [2024] USD 2.56 billion
Forecast Year [2030] USD 4.47 billion
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Venous Catheters Market

The Central Venous Catheters Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population and increasing healthcare and welfare expenditures
    • Increasing government funding providing cancer treatments to patients
    • Growing popularity of antimicrobial catheters
  • Market Restraints
    • High cost of central venous catheters
  • Market Opportunities
    • Development of new central venous catheters
    • Government initiatives to improve the accessibility of cancer treatments
  • Market Challenges
    • Complications associated with prolonged use of central vein approaches

Porter's Five Forces: A Strategic Tool for Navigating the Central Venous Catheters Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Venous Catheters Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Venous Catheters Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Venous Catheters Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Venous Catheters Market

A detailed market share analysis in the Central Venous Catheters Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Venous Catheters Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Venous Catheters Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Venous Catheters Market

A strategic analysis of the Central Venous Catheters Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Venous Catheters Market, highlighting leading vendors and their innovative profiles. These include Amecath Medical Technologies, Angio Dynamics, B. Braun Melsungen AG, Bactiguard AB, Becton, Dickinson and Company, Biosensors International Group, Ltd., BL Lifesciences Pvt. Ltd., C.R. Bard, Fresenius Kabi AG, Henan Tuoren Medical Device Co., Ltd., ICU Medical, Inc., Insung Medical, Kimal Healthcare, Lepu Medical Technology(Beijing)Co.,Ltd., Medical Components, Inc., Medtronic PLC, Polymedicure, QMD by Cirtec Medical, Vogt Medical Vertrieb GmbH, and Vygon SAS.

Market Segmentation & Coverage

This research report categorizes the Central Venous Catheters Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Implanted Ports, Non-Tunneled Central Venous Catheters, Peripherally Inserted CVCs, and Tunneled Central Venous Catheters.
  • Based on Design, market is studied across Double Lumen Central Venous Catheters, Multiple Lumen Central Venous Catheters, and Single Lumen Central Venous Catheters.
  • Based on Material, market is studied across Polyurethane, Rubber, and Silicone.
  • Based on Application, market is studied across Blood Transfusion, Diagnostics & Testing, Drug Administration, and Fluid & Nutrition Administration.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population and increasing healthcare and welfare expenditures
      • 5.1.1.2. Increasing government funding providing cancer treatments to patients
      • 5.1.1.3. Growing popularity of antimicrobial catheters
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of central venous catheters
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new central venous catheters
      • 5.1.3.2. Government initiatives to improve the accessibility of cancer treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with prolonged use of central vein approaches
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Venous Catheters Market, by Product Type

  • 6.1. Introduction
  • 6.2. Implanted Ports
  • 6.3. Non-Tunneled Central Venous Catheters
  • 6.4. Peripherally Inserted CVCs
  • 6.5. Tunneled Central Venous Catheters

7. Central Venous Catheters Market, by Design

  • 7.1. Introduction
  • 7.2. Double Lumen Central Venous Catheters
  • 7.3. Multiple Lumen Central Venous Catheters
  • 7.4. Single Lumen Central Venous Catheters

8. Central Venous Catheters Market, by Material

  • 8.1. Introduction
  • 8.2. Polyurethane
  • 8.3. Rubber
  • 8.4. Silicone

9. Central Venous Catheters Market, by Application

  • 9.1. Introduction
  • 9.2. Blood Transfusion
  • 9.3. Diagnostics & Testing
  • 9.4. Drug Administration
  • 9.5. Fluid & Nutrition Administration

10. Central Venous Catheters Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals & Clinics

11. Americas Central Venous Catheters Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Central Venous Catheters Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Central Venous Catheters Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amecath Medical Technologies
  • 2. Angio Dynamics
  • 3. B. Braun Melsungen AG
  • 4. Bactiguard AB
  • 5. Becton, Dickinson and Company
  • 6. Biosensors International Group, Ltd.
  • 7. BL Lifesciences Pvt. Ltd.
  • 8. C.R. Bard
  • 9. Fresenius Kabi AG
  • 10. Henan Tuoren Medical Device Co., Ltd.
  • 11. ICU Medical, Inc.
  • 12. Insung Medical
  • 13. Kimal Healthcare
  • 14. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 15. Medical Components, Inc.
  • 16. Medtronic PLC
  • 17. Polymedicure
  • 18. QMD by Cirtec Medical
  • 19. Vogt Medical Vertrieb GmbH
  • 20. Vygon SAS
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦